Federal Register / Vol. 75, No. 179 / Thursday, September 16, 2010 / Notices 56549 

Administration, 10903 New Hampshire 

Ave., Bldg. 31, rm. 2417, Silver Spring, 

MD 20993–0002, 301–796–9001, FAX: 

301–847–8533, email: 

diem.ngo@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), codes 

3014512543 and 3014512535. Please 

call the Information Line for up-to-date 

information on this meeting. A notice in 

the Federal Register about last minute 

modifications that impact a previously 

announced advisory committee meeting 

cannot always be published quickly 

enough to provide timely notice. 

Therefore, you should always check the 

agency’s Web site and call the 

appropriate advisory committee hot 

line/phone line to learn about possible 

modifications before coming to the 

meeting. 

Agenda: On November 3, 2010, the 

committees will discuss a number of 

safety concerns with intravenous 

administration of the anti-seizure drugs 

phenytoin and fosphenytoin, including 

the condition known as Purple Glove 

Syndrome, and recommend what 

regulatory actions, if any, are necessary 

to diminish the risks. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before October 20, 2010. 

Oral presentations from the public will 

be scheduled between approximately 1 

p.m. and 2 p.m. Those desiring to make 

formal oral presentations should notify 

the contact person and submit a brief 

statement of the general nature of the 

evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 

or before October 12, 2010. Time 

allotted for each presentation may be 

limited. If the number of registrants 

requesting to speak is greater than can 

be reasonably accommodated during the 

scheduled open public hearing session, 

FDA may conduct a lottery to determine 

the speakers for the scheduled open 

public hearing session. The contact 

person will notify interested persons 

regarding their request to speak by 

October 13, 2010. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Diem-Kieu 

Ngo at least 7 days in advance of the 

meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/Advisory

Committees/AboutAdvisoryCommittees/

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: September 10, 2010. 

Leslie Kux, 

Acting Assistant Commissioner for Policy. 

[FR Doc. 2010–23044 Filed 9–15–10; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

National Institute for Occupational 

Safety and Health (NIOSH), Safety and 

Occupational Health Study Section 

(SOHSS) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the following committee 

meeting. 

Times and Dates: 

8 a.m.–5 p.m., October 7, 2010 (Closed); 

8 a.m.–5 p.m., October 8, 2010 (Closed). 

Place: Embassy Suites Hotel, 1900 

Diagonal Road, Alexandria, Virginia, 

22314, Telephone (703) 684–5900, Fax 

(703) 684–1403. 

Purpose: The Safety and Occupational 

Health Study Section will review, 

discuss, and evaluate grant 

application(s) received in response to 

the Institute’s standard grants review 

and funding cycles pertaining to 

research issues in occupational safety 

and health, and allied areas. 

It is the intent of NIOSH to support 

broad-based research endeavors in 

keeping with the Institute’s program 

goals. This will lead to improved 

understanding and appreciation for the 

magnitude of the aggregate health 

burden associated with occupational 

injuries and illnesses, as well as to 

support more focused research projects, 

which will lead to improvements in the 

delivery of occupational safety and 

health services, and the prevention of 

work-related injury and illness. It is 

anticipated that research funded will 

promote these program goals. 

Matters to be Discussed: The meeting 

agenda includes discussions on matters 

related to the conduct of Study Section 

business and for the study section to 

consider safety and occupational healthrelated grant applications. These 

portions of the meeting will be closed to 

the public in accordance with 

provisions set forth in Section 

552b(c)(4) and (6), Title 5 U.S.C., and 

the Determination of the Director, 

Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention, pursuant to Section 10(d) 

Public Law 92–463. 

Agenda items are subject to change as 

priorities dictate. 

Contact Person for More Information: 

Price Connor, PhD, NIOSH Health 

Scientist, 1600 Clifton Road, NE., 

Mailstop E–20, Atlanta, Georgia 30333, 

Telephone (404) 498–2511, Fax (404) 

498–2571. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities for both CDC and 

the Agency for Toxic Substances and 

Disease Registry. 

Dated: September 10, 2010. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention . 

[FR Doc. 2010–23101 Filed 9–15–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

National Center for Health Statistics 

(NCHS), Classifications and Public 

Health Data Standards Staff, 

Announces the Following Meeting 

Name: ICD–9–CM Coordination and 

Maintenance Committee meeting. 

mstockstill on DSKH9S0YB1PROD with NOTICES

56550 Federal Register / Vol. 75, No. 179 / Thursday, September 16, 2010 / Notices 

Time and Date: 9 a.m.–5:30 p.m., 

September 15–16, 2010. 

Place: Centers for Medicare and 

Medicaid Services (CMS) Auditorium, 

7500 Security Boulevard, Baltimore, 

Maryland. 

Status: Open to the public. 

Purpose: The ICD–9–CM Coordination 

and Maintenance (C&M) Committee will 

hold the last meeting of the 2010 

calendar year cycle on Wednesday and 

Thursday September 15–16, 2010. The 

C&M meeting is a public forum for the 

presentation of proposed modifications 

to the International Classification of 

Diseases, Ninth-Revision, Clinical 

Modification. There will be telephone 

lines available from 9 a.m. until 12:30 

p.m. and 2:15 p.m. until 5:30 p.m. 

(Wednesday) and 9 until 12:30 and 1:30 

until 3:15 p.m. (Thursday) for those who 

are unable to attend the meeting in 

person. The toll-free dial-in number for 

external participants is 1–800–837– 

1935; participant codes for the 

respective sessions are: 888801009, 

88803327, 88805029, and 88808234. 

Participants attending by telephone do 

not need to formally register for the 

meeting. Dial-in lines are available on a 

first come, first served basis. 

Matters To Be Discussed: Tentative 

agenda items include: 

September 15, 2010 

ICD–10 Topics (9–12:30) 

Freeze update 

General Equivalence Maps (GEMs)* 

MS–DRG Impact Analysis 

V28.0 ICD–10 MS–DRGs 

ICD–10–CM/ICD–10–PCS updates 

* Section 10109(c) of the Patient Protection 

and Affordable Care Act and the 

Reconciliation Act of 2010 (PPACA) requires 

the Secretary of Health and Human Services 

(HHS) to task the C&M Committee to convene 

a meeting before January 1, 2011, to receive 

stakeholder input regarding the crosswalk 

between the Ninth and Tenth Revisions of 

the International Classification of Diseases 

(ICD–9, and ICD–10, respectively), posted to 

the CMS Web site at http://www.cms.gov/ 

ICD10, for the purpose of making appropriate 

revisions to said crosswalk. 

Section 10109(c) further states that any 

revised crosswalk be treated as a code set for 

which a standard has been adopted by the 

Secretary, and that revisions to this 

crosswalk be posted to the CMS Web site. 

The C&M Committee will use the first half 

of the first day of the September C&M 

Committee meeting, 9 a.m. to 12:30 p.m. 

Wednesday, September 15, 2010, to fulfill the 

above-referenced PPACA requirements for 

this meeting to be held prior to January 1, 

2011, and receive public input regarding the 

above-referenced crosswalk revision. 

No other meeting will be convened by the 

C&M Committee for this purpose. Interested 

parties and stakeholders should be prepared 

to submit their written comments and other 

relevant documentation at the meeting, or no 

later than November 12, 2010 to the 

following addresses: 

ICD–9–CM procedure topics: 

Contrast Dye Removal 

Endovascular partial occlusion of 

abdominal aorta 

Endovascular Intracranial Aneurysm 

Embolization 

Fenestrated AAA Endovascular Graft 

Implantation of an Anti-Microbial 

Envelope 

Pulmonary Artery Pressure Monitoring 

Addenda (procedures) 

September 16, 2010 

Corticobasal degeneration 

Complication of stem cell transplant 

Gastroparesis 

Glaucoma 

Hepatopulmonary syndrome 

Interstitial lung diseases 

Malnutrition 

Mesh erosion 

Pseudobulbar affect 

Transfusion transmitted infections 

Genitourinary conditions 

Addenda (diagnoses) 

Contact Person for Additional 

Information: Donna Pickett, Medical 

Systems Administrator, Classifications 

and Public Health Data Standards Staff, 

NCHS, 3311 Toledo Road, Room 2337, 

Hyattsville, Maryland 20782, e-mail 

dfp4@cdc.gov, telephone 301–458–4434 

(diagnosis), Mady Hue, Health 

Insurance Specialist, Division of Acute 

Care, CMS, 7500 Security Blvd., 

Baltimore, Maryland 21244, e-mail 

marilu.hue@cms.hhs.gov, telephone 

410–786–4510 (procedures). 

Note: CMS and NCHS will no longer be 

providing paper copies of handouts for the 

meeting. Electronic copies of all meeting 

materials will be posted on the CMS and 

NCHS Web sites prior to the meeting at 

http://www.cms.hhs.gov/ICD9Provider

DiagnosticCodes/03_

meetings.asp#TopOfPage and http:// 

www.cdc.gov/nchs/icd/icd9cm_

maintenance.htm. 

Notice: Because of increased security 

requirements CMS has instituted 

stringent procedures for entrance into 

the building by non-government 

employees. Persons without a 

government I.D. will need to show an 

official form of picture I.D. (such as a 

drivers license), and sign-in at the 

security desk upon entering the 

building. 

Those who wish to attend a specific 

ICD–9–CM C&M meeting in the CMS 

auditorium must submit their name and 

organization in addition to the meeting 

visitor list. Those wishing to attend the 

September 15–16, 2010 meeting must 

submit their name and organization by 

September 10, 2010 for inclusion on the 

visitor list. This visitor list will be 

maintained at the front desk of the CMS 

building and used by the guards to 

admit visitors to the meeting. Those 

who attended previous ICD–9–CM C&M 

meetings will no longer be 

automatically added to the visitor list. 

You must request inclusion of your 

name prior to each meeting you attend. 

Register to attend the meeting on-line 

at: http://www.cms.hhs.gov/apps/ 

events/. 

For questions about the registration 

process please contact Mady Hue (410– 

786–4510 or Marilu.hue@cms.hhs.gov). 

Notice: This is a public meeting. However, 

because of fire code requirements, should the 

number of attendants meet the capacity of the 

room, the meeting will be closed. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both CDC 

and the Agency for Toxic Substances 

and Disease Registry. 

Dated: September 8, 2010. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2010–23092 Filed 9–15–10; 8:45 am] 

BILLING CODE 4160–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of meetings of the National 

Advisory Neurological Disorders and 

Stroke Council. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in sections 

552b(c)(6), Title 5 U.S.C., as amended 

for the review, discussion, and 

evaluation of individual intramural 

programs and projects conducted they 

the National Institute of Neurological 

Disorders and Stroke, including 

consideration of personnel 

qualifications and performance, and the 

competence of individual investigators, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Board of Scientific 

Counselors, National Institute of 

Neurological Disorders and Stroke. 

Date: October 24–25, 2010. 

Time: 7 p.m. to 6:30 p.m. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individual investigators. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

mstockstill on DSKH9S0YB1PROD with NOTICES